• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead - ACUITY Long-Term Registry

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P010012 S160/ PAS001
Date Current Protocol Accepted 01/20/2017
Study Name OSB Lead - ACUITY Long-Term Registry
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Adolescent: 13-18 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description prospective, non-randomized, multi-center registry
Study Population Description The study population will consist of patients who: were successfully implanted with the ACUITY Spiral Lead, meet the study criteria.
Sample Size 1,700 patients, 150 sites
Data Collection Chronic LV lead-related complication-free rate over a five year follow- up period
Follow-up Visits and Length of Follow-up Patients will be followed until they have completed five years of

follow-up from implant or until death, withdrawal, or closure of the registry.

Patients will have an in-clinic follow-up visit one month (15 to 29

days) post implant and then subsequently be followed according to the center¿s standard follow-up schedule, with complete in-clinic system interrogation recommended to be at least once every six months.

OSB Lead - ACUITY Long-Term Registry Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
18 month report 11/14/2009 11/13/2009 On Time
2 year report 05/16/2010 05/14/2010 On Time
30 month report 11/14/2010 11/15/2010 Overdue/Received
3 year report 05/16/2011 05/12/2011 On Time
42 month report 11/14/2011 11/14/2011 On Time
4 year report 05/15/2012 05/15/2012 On Time
54 month report 11/13/2012 11/13/2012 On Time
5 year report 05/15/2013 05/13/2013 On Time
interim report 11/13/2013 11/07/2013 On Time
6 year report 05/15/2014 05/05/2014 On Time
78 month report 11/15/2014 11/13/2014 On Time
7 year report 05/15/2015 05/12/2015 On Time
interim report 11/15/2015 11/04/2015 On Time
8 year report 07/14/2016 06/27/2016 On Time
102 month report 11/14/2016 11/14/2016 On Time
Final Report 03/31/2021 03/05/2018 On Time

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links